Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 12164 pages

Showing 1 - 50


gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Zev A. Wainberg, MD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Bemarituzumab and FOLFOX

Zev A. Wainberg, MD, of UCLA Medical Center, discusses phase II results from the FIGHT study, which combined bemarituzumab with modified FOLFOX6 in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma. This is reportedly the first randomized trial of any FGFR inhibitor, ...

skin cancer

FDA Pipeline: Two Fast Track Designations for Cavrotolimod in Nonmelanoma Skin Cancers

The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). The designations include cavrotolimod in combination with anti–PD-1 therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma refractory to prior...

lymphoma

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

On January 14, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for pediatric patients aged 1 year and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been ...

covid-19

COA Submits Letter to Governors, Public Health Officials to Request Independent Oncology Practices Be Given Priority Approval to Administer COVID-19 Vaccines

Today, leadership from the Community Oncology Alliance (COA) sent a letter urging the nation's governors and public health officials to prioritize supplying cancer treatment practices with COVID-19 vaccines and allowing the practices to administer the vaccines. The letter, signed by Kashyap Patel,...

breast cancer

Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial

Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...

breast cancer
gynecologic cancers
colorectal cancer

Rates of Eligible People Missing Timely Cancer Screenings: A Canadian Analysis

New research published by Abdel-Rahman in JNCCN—Journal of the National Comprehensive Cancer Network found more than one-third of eligible people miss timely screening tests for colorectal cancer, and at least one-quarter appear to miss timely screening tests for breast and cervical cancers....

breast cancer
pain management

New Study Examines Patterns of Opioid Use Among Patients With Metastatic Breast Cancer

Some patients with metastatic breast cancer are taking smaller doses of opioid prescriptions over decreased amounts of time, according to results published by Shen et al in Scientific Reports. Researchers said that the results indicate that clinicians may be more aware of the negative impacts of...

issues in oncology
lung cancer
gynecologic cancers

Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’

Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...

Sean Khozin, MD, MPH, Named New Chief Executive Officer of ASCO’s CancerLinQ

Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. A board-certified oncologist, physician-scientist, and data science expert, Dr. Khozin is a proven leader and visionary in deploying cutting-edge data science and technology...

multiple myeloma
immunotherapy

Expert Point of View: Sagar Lonial, MD

Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial for The ASCO Post. “APOLLO is a highly awaited study, as the use of daratumumab plus...

breast cancer

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The ...

skin cancer

New Study Investigates Role of Ultraviolet Radiation in Conjunctival Melanoma

Ultraviolet (UV) radiation may contribute to the development of a rare type of eye cancer, conjunctival melanoma, according to research published by Mundra et al in Nature Communications. The new study has revealed similar genetic changes in patients with conjunctival melanoma to those with...

cns cancers

Association Between Toxoplasma gondii Infection and Risk of Glioma

A new study published by Hodge et al in the International Journal of Cancer suggests a link between Toxoplasma gondii infection and the risk of glioma in adults. The report found that people who have glioma are more likely to have antibodies to T gondii than a similar group that was cancer-free....

breast cancer

Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy

Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; the best sentinel lymph node biopsy technique for patients with node-positive disease who convert to...

pancreatic cancer

Can Use of Opioids Contribute to Pancreatic Cancer Risk?

Researchers have found evidence that opioid use may be an unidentified risk factor contributing to the increasing incidence of pancreatic cancer in the United States. These findings were published by Barlass et al in PLOS One. The use of prescription opioids for the management of chronic pain has...

head and neck cancer

Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers

In a comprehensive molecular characterization of the most common type of head and neck cancer, researchers from the United States and Poland have clarified the contribution of key cancer-associated genes, proteins, and signaling pathways in these cancers, while proposing possible new treatment...

covid-19

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health-Care Providers and Clinical Laboratory Staff

The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and health-care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests....

leukemia
genomics/genetics

Sara Zarnegar-Lumley, MD, on AML: Prognostic Effects of IDH Mutations

Sara Zarnegar-Lumley, MD, of Vanderbilt University Medical Center, discusses an analysis of a large cohort confirming the age-associated prevalence of IDH mutations in patients, across the age spectrum, with acute myeloid leukemia and therapeutic implications. IDH-mutated genes were found to...

lung cancer
prostate cancer
immunotherapy
genomics/genetics

FDA Pipeline: Two Reviews in NSCLC, Plus Prescribing Information Update for Darolutamide

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to lorlatinib in ALK-positive non–small cell lung cancer (NSCLC) and Breakthrough Therapy designation to the combination of tiragolumab plus atezolizumab in NSCLC with high PD-L1 expression. The FDA also updated the...

prostate cancer

Does Following a Mediterranean Diet Reduce the Risk of Disease Progression in Men on Active Surveillance for Prostate Cancer?

In a study examining the effect of a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style...

solid tumors
hematologic malignancies
covid-19

Immune Response to COVID-19 Reduced in Patients With Hematologic Malignancies vs Solid Tumors

Patients with hematologic malignancies varied in their immune response to COVID-19, and some struggled to clear the infection, according to new research published by Abdul-Jawad in Cancer Cell. In contrast, most patients with solid tumors—even those with advanced cancer—were shown to be able to...

hematologic malignancies
lymphoma
multiple myeloma
issues in oncology
palliative care

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Lena E. Winestone, MD, MSHP, of the University of California, San Francisco and Benioff Children’s Hospital, reviews different aspects of bias in treatment delivery, including patient selection for clinical trials; racial and ethnic disparities in survival for indolent non-Hodgkin diffuse large...

breast cancer

Distinct T-Cell Signature in Black Patients With Breast Cancer May Contribute to More Aggressive Disease

A research team has revealed a distinct molecular signature in the tumor tissues of Black patients with breast cancer. The new work, published by Yao et al in JNCI: Journal of the National Cancer Institute, reported that an elevated number of “exhausted,” nonfunctional T cells appears to lead to...

issues in oncology

Facebook Posts and the Spread of Incorrect Information About Perceived Risks of HPV Vaccination

The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). HPV is associated with health problems—including cancers—but a vaccine for the virus has been available since 2006. The CDC...

leukemia
genomics/genetics

Christian Marinaccio, PhD Candidate: Genetic Driver May Play a Role in Progression of Myeloproliferative Neoplasms to AML

Christian Marinaccio, PhD Candidate, of Northwestern University, describes research he is conducting in the laboratory of John D. Crispino, PhD, which shows the loss of the tumor suppressor gene LKB1/STK11 facilitates progression of myeloproliferative neoplasms to acute myeloid leukemia (Abstract...

skin cancer
genomics/genetics

New Study Explores the Use of Focused Ultradeep DNA Sequencing to Quantify Skin Cancer Risk

Recent research has shed new light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. A study published by Lei Wei, PhD, and colleagues in Science Advances detailed a method to measure the...

prostate cancer
symptom management

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer

Many patients with prostate cancer are treated with androgen-deprivation therapy. However, patients receiving androgen-deprivation therapy often experience higher levels of fatigue, depression, and cognitive impairment. In a new study published by Hoogland et al in the journal Cancer, researchers...

lymphoma

Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II data from the Primo trial, which support continued evaluation of duvelisib as a treatment option for relapsed or refractory peripheral T-cell lymphoma due to consistent response rates (Abstract 44).

lymphoma

Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Tycel J. Phillips, MD, of the University of Michigan Rogel Cancer Center, discusses phase II data from the CITADEL-204 study, showing that patients with relapsed or refractory marginal zone lymphoma who were not previously treated with a Bruton’s tyrosine kinase inhibitor achieved rapid and durable ...

gastrointestinal cancer

Study Focuses on Single-Cell Analysis of Peritoneal Carcinomatosis

Researchers profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis and defined the extensive cellular heterogeneity, as well as identified two distinct cell subtypes correlated with patient survival. The findings were published by Wang et al in Nature Medicine....

prostate cancer
genomics/genetics

Multiancestry Meta-analysis of Prostate Cancer Genetics

A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever...

covid-19

FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines

On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...

lymphoma

Steven M. Horwitz, MD, on T-Cell Lymphoma: Update on Allogeneic Hematopoietic Transplant

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses data from the largest multicenter retrospective analysis of allogeneic hematopoietic transplantation, which supports its curative potential in patients with mature T-cell lymphoma, a group marked by poor survival and...

survivorship

Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy?

A study published by Hyuna Sung, PhD, and colleagues in JAMA found that adult-onset cancer survivors may have a greater risk of developing and dying from subsequent primary cancers than the general population. Cancers associated with smoking or obesity accounted for a majority of subsequent primary ...

lung cancer
immunotherapy

Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market

On December 29, Bristol Myers Squibb issued the following statement on nivolumab’s small cell lung cancer (SCLC) indication in the United States. In 2018, nivolumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCLC whose disease...

gynecologic cancers
global cancer care

Global Burden of Cervical Cancer and Association With HIV

A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...

gynecologic cancers
breast cancer

Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers

A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...

global cancer care

GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths

On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...

covid-19

FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine

On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...

issues in oncology

American Cancer Society Report Identifies Critical Gaps and Research Opportunities for Improved Cancer Care

A new report found that despite progress in the decline of cancer mortality, there are still critical gaps, including the need to develop better tools and explore research opportunities that would lead to limiting cancer as a major health concern. This blueprint article completes an eight-part...

issues in oncology

Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients

Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...

covid-19

NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches

The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...

lung cancer
covid-19

Effect of the COVID-19 Pandemic on Lung Cancer Screening

Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...

Roswell Park Experts Named to Highly Cited Researchers List

Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...

Susan E. Hankinson, ScD, MPH, Receives AACR Distinguished Lectureship in Breast Cancer Research Award

The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) honored Susan E. Hankinson, ScD, MPH, for her significant contributions to breast cancer research. Dr. Hankinson received the 2020 AACR Distinguished Lectureship in Breast Cancer Research award...

Northwell Invests $6M in Comprehensive Cancer Center in Riverhead, New York

Northwell Health recently announced that it will open a $6.2 million, 11,300-square-foot comprehensive cancer center in Riverhead, New York, by the end of this year. The new facility will provide residents of the East End of Long Island access to integrated cancer services in a conveniently located ...

John Ryan, JD, Named Senior Vice President and General Counsel at Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has appointed John Ryan, JD, as its Senior Vice President, General Counsel, and Chief Governance Officer. Mr. Ryan has extensive expertise representing health-care and life sciences organizations in public company and nonprofit settings. He has managed a wide range of...

Two Leading Institutions Collaborate to Advance Treatment of Smoldering Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute have jointly announced a pioneering research collaboration in smoldering myeloma, a precursor disease to multiple myeloma. Combining the strengths of the MMRF, a leader in multiple myeloma data generation, and...

lung cancer

FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC

On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...

Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASH’s Red Journal

The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...

Advertisement

Advertisement



Advertisement